18 results about "Anti tuberculosis" patented technology

Provided here are nucleic acid constructs containing a Mycobacterium tuberculosis genome comprising a mutation (such as a deletion) of the sigH gene (AsigH) and a mutation (such as a deletion) of at least one additional gene, and mutant Mycobacterium tuberculosis encoded by the nucleic acid constructs. Also provided are methods of making such nucleic acid constructs and Mycobacterium tuberculosis mutants, and uses thereof. The construct can stimulate an immune response against Mycobacterium tuberculosis in a subject, and can be used as live attenuated vaccines.

The invention discloses an application of a single base / amino acid mutation of a bovine DDX58 gene in anti-tuberculosis, belongs to the technical field of bovine tuberculosis prevention and treatment, an application of a single base mutation of a bovine DDX58 gene in anti-tuberculosis, the CDS sequence of the bovine DDX58 gene is shown in SEQ ID NO.1, the amino acid sequence is shown in SEQ ID NO.2, and the single base mutation is located at the 11603839th nucleotide from the 5′ end of chromosome 8 of the ARS-UCD1.2 version reference sequence of the bovine genome. The single base mutation of the bovine DDX58 gene provided by the present invention has a significant effect on the production amount of type I interferon and the clearance effect of macrophages on Mycobacterium tuberculosis, and is highly linked to the anti-tuberculosis trait of the bovine; the single base / amino acid mutation of the bovine DDX58 gene provided can be used as a bovine tuberculosis resistance linkage site, used for genotype selection in bovine tuberculosis resistance breeding, thereby simplifying the selection method and shortening the selection time.

The present invention relates to novel rufamycin analogs that target the ClpC1 protease. The compounds of the present invention have antibacterial activity, e.g., with anti-tuberculosis properties, and are useful in the treatment of e.g. Tuberculosis.

The present invention is directed to a vaccine composition against a disease caused by Mycobacterium tuberculosis, said composition comprising at least four nucleic acids selected from the following groups: a. a nucleic acid encoding an Ag85A, Ag85B, or Ag85C antigen; b. a nucleic acid encoding a resuscitation promoting factor (Rpf) selected from the group consisting of: RpfA, RpfB, RpfC, RpfD and RpfE; c. a nucleic acid encoding a PE / PPE antigen selected from the group consisting of: PE5, PE13, PE15, PE29, PE31, PPE1, PPE2, PPE18, PPE20, and PPE68; d. a nucleic acid encoding a disease-reactivation-related antigen selected from the group consisting of: Rv1234 / MMAR_4207, and Rv0359 / MMAR_0678, wherein said vaccine composition comprises at least one nucleic acid from each of group a, b, and c; and wherein the nucleic acids are provided on one or more nucleic acids constructs.

The present application relates to the field of biotechnology, and in particular to an application of Rv0087, a target against Mycobacterium tuberculosis. Specifically, it is at least one of the following applications of a substance that inhibits the activity of the Rv0087 protein and / or a substance that reduces the content of the Rv0087 protein: 1) Application in the preparation of products for the treatment or auxiliary treatment of tuberculosis; 2) Application in the preparation of products for the prevention or inhibition of Mycobacterium tuberculosis infection. The Rv0087 protein secreted by Mycobacterium tuberculosis can interact with the host target protein PKCγ, thereby promoting the intracellular survival of Mycobacterium tuberculosis. Therefore, this not only provides a new target for clinical tuberculosis treatment and anti-tuberculosis drug development, but also provides guidance for the research and development of anti-tuberculosis drugs targeting the Rv0087 domain.

The present application relates to the technical field of pharmacy, in particular to application of compound Diaporterpene C in preparation of mycobacterium tuberculosis tyrosine phosphatase inhibitor. The present application provides application of compound Diaporterpene C in preparation of mycobacterium tuberculosis tyrosine phosphatase inhibitor, the compound can significantly inhibit the activity of key virulence factor tyrosine phosphatase MptpA and MptpB of mycobacterium tuberculosis, can be used as tyrosine phosphatase inhibitor with MptpA and / or MptpB as target, and can be further developed as anti-tuberculosis drug. The compound shows good anti-tuberculosis activity by inhibiting pathogenic signal pathway of pathogenic bacteria, and has important clinical application potential and development value in tuberculosis treatment.

The invention discloses application of an STX6 gene as a target spot in prevention and treatment of tuberculosis, the survival of mycobacterium bovis, mycobacterium tuberculosis, BCG and mycobacterium smegmatis in host cells can be remarkably inhibited by knocking out or knocking down the expression of the STX6 gene, the host cell death induced by the mycobacterium bovis and the mycobacterium tuberculosis is inhibited, and the normal proliferation of the host cells is not influenced. Meanwhile, the STX6 is highly conserved in mammals, so that the STX6 can be widely applied to prevention and treatment of tuberculosis caused by humans and animals, can also be used as a target for gene editing animal design, is applied to genetic therapy and disease-resistant breeding, and has rich application and economic values.

The invention relates to the technical field of biological medicines, and discloses application of an IGF1R (Insulin-like Growth Factor 1 Receptor) gene as an anti-tuberculosis target spot in treatment and / or diagnosis of tuberculosis. The IGF1R gene is related to the susceptibility of tuberculosis. The IGF1R gene is used for regulating a tumor-related pathway and a PI3K-Akt signal pathway, so that host-oriented anti-tuberculosis is realized. BEAS-2B cells are stimulated through PPD, it is proved that the IGF1R gene has susceptibility correlation with TB, the correlation between the IGF1R gene and a tumor-related pathway and a PI3K-Akt signal pathway and related key functional genes are determined, a new thought is provided for research on TB morbidity and tuberculosis susceptibility, and a foundation is laid for the IGF1R gene serving as a new target in TB diagnosis and treatment.

The present invention discloses the application of bovine SP110 gene splicing editing in enhancing the anti-tuberculosis ability of cattle, belonging to the technical field of bovine anti-tuberculosis breeding. The present invention starts from splicing-related cis-acting elements, and regulates the alternative splicing reaction of bovine SP110 by introducing cis-acting elements, thereby affecting the anti-tuberculosis ability of cattle. The cis-acting element sequence is named the pre-SAND-exon sequence, which is located in exon 12 and the adjacent 5'-terminal intron 12 of the human or equine SP110 gene, and the sequences are shown in SEQ ID NO.1 and SEQ ID NO.2. The present invention first regulates the alternative splicing of the bovine SP110 gene by introducing the pre-SAND-exon sequence into the bovine SP110 gene, reduces the expression abundance of the spliceosome bSP110c with lower anti-tuberculosis ability, and regulates the higher abundances of the spliceosomes bSP110a and bSP110b with anti-tuberculosis infection ability. The provided bovine SP110 gene splicing editing can effectively improve the anti-tuberculosis ability of cattle, can be used for the breeding of anti-tuberculosis cattle, effectively simplifies the breeding method, improves the breeding efficiency, and saves the breeding cost.

The invention relates to the technical field of biological medicine, in particular to application of salvianolic acid in preparation of an anti-tuberculosis drug. The invention provides application of salvianolic acid A or pharmaceutically acceptable salt thereof in preparation of the anti-tuberculosis drug, the molecular formula of the salvianolic acid A is C26H22O10, and the structural formula is shown in formula I. When the salvianolic acid A is applied to preparation of the anti-tuberculosis drug, a brand new material basis is provided for research and development of the anti-tuberculosis drug, damage of the drug to normal tissues of a human body is reduced, and the anti-tuberculosis drug can be applied to preparation of the anti-tuberculosis drug. Toxic and side effects are reduced. From the aspect of action mechanism, the salvianolic acid A has various biological activities such as inflammation resistance, oxidation resistance and immunoregulation, and can inhibit the growth and reproduction of mycobacterium tuberculosis and enhance the immune defense capability of the body to tubercle bacillus through the multi-target synergistic effect, thereby achieving the purpose of treating tuberculosis.

The invention discloses an application of cattle SP110 gene splicing editing in enhancing the anti-tuberculosis ability of cattle, and belongs to the technical field of cattle anti-tuberculosis breeding, starting from splicing related cis-acting elements, the variable splicing reaction of the cattle SP110 is regulated by introducing the cis-acting elements, so that the anti-tuberculosis ability of the cattle is influenced. The sequence of the cis-acting element is named as a pre-SAND-exon sequence, the cis-acting element is located on the 12th exon of a human or horse SP110 gene and the 12th intron adjacent to the 5'end of the human or horse SP110 gene, and the sequences of the cis-acting element are shown as SEQ ID NO.1 and SEQ ID NO.2. According to the invention, the pre-SAND-exon sequence is introduced into the cattle SP110 gene for the first time, so that the variable splicing of the cattle SP110 gene is regulated and controlled, the expression abundance of a splicing body bSP110c with relatively low anti-tuberculosis capability is reduced, and the abundance of bSP110a and bSP110b splicing bodies with anti-tuberculosis infection capability is regulated and controlled to be higher. The provided cattle SP110 gene splicing editing can effectively improve the anti-tuberculosis ability of cattle, can be used for breeding anti-tuberculosis cattle, effectively simplifies the breeding method, improves the breeding efficiency, and saves the breeding cost.

The invention relates to the technical field of biology, in particular to application of a target Rv0087 for resisting mycobacterium tuberculosis. Specifically, the invention relates to at least one of the following applications of a substance for inhibiting the activity of the Rv0087 protein and / or a substance for reducing the content of the Rv0087 protein: 1) an application in preparation of a product for treatment or adjuvant treatment of tuberculosis; and 2) application in preparation of products for preventing or inhibiting mycobacterium tuberculosis infection. The Rv0087 protein secreted based on the mycobacterium tuberculosis can interact with host target protein PKC gamma, so that the intracellular survival of the mycobacterium tuberculosis is promoted. Therefore, a new target spot is provided for clinical tuberculosis treatment and development of anti-tuberculosis drugs, and guidance is provided for research, development and design of the anti-tuberculosis drugs targeting the Rv0087 structural domain.

The present invention relates to new norbornen analogues of formula (I), wherein the norbornen moiety is in R5 and to the use of norbornen analogues as a drug, in particular for the prevention and / or treatment of a mycobacterial infection or for the prevention and / or treatment of a disease caused by infection with a mycobacterium.

The present invention belongs to the technical field of animal husbandry, and specifically relates to the use of an expression inhibitor of bovine CXXC1 protein in the preparation of a product for inhibiting tuberculosis. Experimental verification shows that the interference of CXXC1 inhibits the survival of tuberculosis, indicating that the expression inhibitor of bovine CXXC1 protein can be used as a potential substance for resisting tuberculosis infection, and bovine CXXC1 protein can provide new ideas for breeding anti-tuberculosis animals.

The invention relates to the technical field of pharmacy, and provides an isoniazide tablet and a preparation method thereof.The isoniazide tablet comprises isoniazide, microcrystalline cellulose, pregelatinized starch, polyvinylpolypyrrolidone, colloidal silicon dioxide, magnesium stearate and hydrogenated vegetable oil; the preparation method comprises the following steps: weighing the raw material components according to the mass ratio, and sequentially adding the isoniazide and the colloidal silicon dioxide into a mixer for mixing; sequentially adding microcrystalline cellulose, pregelatinized starch, cross-linked povidone and the pretreated hydrogenated vegetable oil into the mixing machine, and mixing the microcrystalline cellulose, the pregelatinized starch, the cross-linked povidone and the pretreated hydrogenated vegetable oil; finally, magnesium stearate is added into the mixing machine to be mixed, and a mixed material is obtained; the isoniazide tablet which is good in compressibility, not easy to break, low in impurity content and excellent in performance is prepared by strictly regulating and controlling the components and the content of the isoniazide tablet and controlling specific parameters of the steps of raw material mixing, tabletting and the like in the production process, and the isoniazide tablet has higher safety and is more beneficial to the use of isoniazide as an anti-tuberculosis first-line medicine.

The invention belongs to the field of biological medicines, and provides an application of acetoacetic acid and derivatives thereof in preparation of medicines for treating or relieving hepatotoxicity caused by antituberculosis medicines. The hepatocytes formed by differentiation of human induced pluripotent stem cells are verified, and hydrazine is a metabolite with the strongest toxicity, so that the content of acetoacetic acid in the metabolite in the cells is reduced. Acetoacetic acid is one of main ketone metabolites in the ketone metabolism process, and cells can convert acetoacetic acid into acetoacetyl coenzyme A through succinyl coenzyme A: 3-oxo acid coenzyme A transferase. According to the invention, the OXCT1 gene in the human induced pluripotent stem cell is knocked out through CRISPR-cas9 and the human induced pluripotent stem cell is differentiated into the hepatocyte, so that the knockout of the OXCT1 gene increases the content of acetoacetic acid and reduces hepatic differentiation cell death caused by hydrazine.

The invention discloses recombinant mycobacterium smegmatis expressing Rv0222 and application of the recombinant mycobacterium smegmatis, and belongs to the technical field of biology. The recombinant mycobacterium smegmatis is constructed by transferring an Rv0222 gene into the mycobacterium smegmatis, and the nucleotide sequence of the Rv0222 gene is as shown in SEQ ID No: 1. The recombinant vector is constructed through the shuttle expression vector, the mycobacterium smegmatis is electrically transformed to obtain the recombinant mycobacterium smegmatis, the mechanism of the Rv0222 for regulating inherent immunity is explored by using the recombinant mycobacterium smegmatis, and a theoretical basis is provided for screening of new anti-tuberculosis drugs targeting the Rv0222.

The invention discloses application of a PAPSS2 gene as a target spot in prevention and treatment of tuberculosis, the PAPSS2 gene is knocked out or knocked down, so that survival of mycobacterium bovis, mycobacterium tuberculosis, BCG and mycobacterium smegmatis in host cells can be remarkably inhibited, and normal proliferation of the host cells is not affected. Meanwhile, the PAPSS2 is highly conserved in mammals, so that the PAPSS2 can be widely applied to prevention and treatment of tuberculosis caused by humans and animals, can also be used as a target for gene editing animal design, is applied to genetic therapy and disease-resistant breeding, and has rich application and economic values.